R&D expenditure will rise in the coming quarters: Biocon Biologics MD

In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business

Biocon saw its net profit rising 11 per cent to Rs 187 crore in the third quarter (September to December) even as revenue grew 18 per cent to Rs 2,223 crore. The bright spark for the business was its biosimilars segment which saw a 28 per cent rise in income to Rs 981 crore.

Biocon Biologics managing director Dr Arun Chandavarkar spoke to Business Standard’s Deepsekhar Choudhury on how its interchangeable insulin biosimilar has driven the business, R&D spends in the future and more. Edited excerpts:

What was the revenue impact of interchangeable Semglee on the biologics business in Q3?